NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03863860,A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients,https://clinicaltrials.gov/study/NCT03863860,,UNKNOWN,"To evaluate the efficacy, safety tolerability of maintenance therapy with Fluzoparib(A PARP inhibitor) versus placebo in Chinese patients with recurrent ovarian cancer who achieved a complete response (CR) or partial response (PR) after platinum-based chemotherapy",NO,Ovarian Cancer,DRUG: Fluzoparib capsules|DRUG: Placebo capsules,"Progression free survival(PFS) by Blinded Independent Review Committee (BIRC) in relapsed ovarian cancer patients, Defined as progression free survival per RECIST 1.1 criteria, up to 2 years|Progression free survival(PFS) by BIRC in relapsed ovarian cancer patients with Breast cancer susceptibility gene(BRCA) mutant, Defined as progression free survival per RECIST 1.1 criteria, up to 2 years","Progression free survival(PFS) in relapsed ovarian cancer patients, PFS is Progression-Free-Survival per RECIST 1.1 criteria, up to 2 years|Time to progression(TTP) by Gynecological Cancer Intergroup(GCIG) CA 125 criteria, TTP is Time to Progression, up to 2 years|Chemotherapy free interval (CFI) CFI, CFI is the time from last platinum dose until initiation of next anticancer therapy (excluding maintenance therapy if used following the penultimate regimen), up to 2 years|overall survival(OS), OS is the time interval from the start of treatment to death due to any reason or lost of follow-up, up to 3 years|Objective Response Rate, Objective Response Rate complete or partial response per RECIST 1.1 criteria, At baseline,at the time point of every 12 weeks, up to 2 years|Adverse Events(AEs) and Serious Adverse Events (SAEs), assess the safety and tolerability of Fluzoparib maintenance monotherapy in platinum sensitive relapsed ovarian cancer patients by record the number of Participants with of AEs and SAEs, and the proportion of patients with AEs and SAEs, etc., from the first drug administration to within 30 days for the last treatment dose",,"Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,252,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",FZPL-â…¢-301-OC,2019-04-30,2022-12-31,2022-12-31,2019-03-05,,2022-06-13,"Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China",
